Advertisement


Akihiro Ohba, MD, on Biliary Tract Cancer: New Findings on Fam-Trastuzumab Deruxtecan-nxki

2022 ASCO Annual Meeting

Advertisement

Akihiro Ohba, MD, of Japan’s National Cancer Center Hospital, discusses phase II data from the HERB trial on fam-trastuzumab deruxtecan-nxki, which showed activity in patients with HER2-expressing unresectable or recurrent biliary tract cancer (Abstract 4006).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The HERB trial is an investigator-initiated, multicenter, single-arm Phase II trial which evaluate the efficacy and the safety of trastuzumab deruxtecan, T-DXd, in patient with HER2-expressing biliary tract cancers. In 2016, when we began to design this study, there were no effective second-line chemotherapy regiments and no effective targeted therapies for biliary tract cancers. Moreover, even breast and gastric cancers, T-DXd did not have strong evidence, but the early efficacy signs of T-DXd in breast cancer and the HER2-positive rate in biliary tract cancer made us decide to conduct this trial. Before we ran the trial, we examined the tissue sample of more than 400 biliary tract cancer cases by HER2 testing and found that HER2 expression patterns were more similar to gastric cancer than breast cancer. We used the diagnostic criterion for this trial. Patient was screened in 30 Japanese centers taking part in the SCRUM-Japan project and the trial was conducted in five of these 30 centers. A key inclusion criteria was histologically confirmed unresectable or recurrent biliary tract cancer, centrally confirmed HER2-expressing status and refractory or intolerant to treatment, including gemcitabine. The primary endpoint was confirmed objective response rate in HER2-positive patient by blinded independent central review, BICR. During my year, we enrolled 32 patient, 24 HER2-positive, and eight were HER2-low-expressing. Two ineligible patients were excluded from the efficacy analysis. Of the 22 HER2-positive eligible patients, the primary endpoint of the confirmed objective response rate was 36.4%. Among the eight HER2-low-expressing patients, one patient achieved a partial response. The duration of response, progression-free survival and overall survival, was longer than we expected. In terms of adverse events, the most common adverse events were hematological toxicities such as anemia and neutrophil count decreased and white blood cell count decreased. They were more frequent than in clinical trials of T-DXd in other cancer types. Interstitial lung disease occurred in 25% of patient, including two grade-five cases. Also, we could not find obvious risk factors. We should pay attention to all this when we're using this drug, especially for biliary tract cancers. We think that T-DXd showed promising activity in HER2-expressing biliary tract cancers. Further evaluations are needed to confirm these findings in this patient population. On the other hand, such a large-scale trial is difficult for a limited population of HER2-positive biliary tract cancers, and we also discussed the way of drug approval based on the result of this study. I hope that such an effective drug will be available in our clinical practice.

Related Videos

Bladder Cancer

Karim Chamie, MD, on Bladder Cancer: Final Results on N-803 and Bacillus Calmette-Guérin

Karim Chamie, MD, of the University of California, Los Angeles, discusses final clinical results on combining the superagonist N-803 with bacillus Calmette-Guérin (BCG) in patients whose carcinoma in situ and high-grade non–muscle-invasive bladder cancers are unresponsive to BCG alone. Of note, cystectomy was avoided in more than 90% of patients with 2 years of follow-up (Abstract 4508).

Myelodysplastic Syndromes

Ruben A. Mesa, MD, on Myelofibrosis: Phase III Results on Momelotinib vs Danazol

Ruben A. Mesa, MD, of Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses new findings from the MOMENTUM study. This trial showed that in symptomatic and anemic patients with myelofibrosis, momelotinib was superior to danazol for symptom and spleen responses, as well as transfusion requirements (Abstract 7002).

Bladder Cancer

Sumanta K. Pal, MD, on Urothelial Carcinoma: New Results on Cabozantinib Plus Atezolizumab

Sumanta K. Pal, MD, of City of Hope National Medical Center, discusses findings from the COSMIC-021 study, which showed that cabozantinib plus atezolizumab demonstrated encouraging clinical activity with manageable toxicity in patients with inoperable locally advanced or metastatic urothelial carcinoma. The combination was administered as first-line therapy in cisplatin-based chemotherapy–eligible and –ineligible patients and as second- or later-line treatment in those who received prior immune checkpoint inhibitors (Abstract 4504).

Lung Cancer
Genomics/Genetics

Gilberto de Lima Lopes, Jr, MD, MBA, and Matthew Krebs, PhD, on NSCLC: Updated Results With Amivantamab-vmjw

Gilberto de Lima Lopes, Jr, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, and Matthew Krebs, PhD, of The University of Manchester and The Christie NHS Foundation Trust, discuss results from the CHRYSALIS study. The trial showed that the bispecific antibody amivantamab-vmjw demonstrated antitumor activity, even after prior treatment, in patients with non–small cell lung cancer that exhibits the MET exon 14 skipping mutation (Abstract 9008).

Supportive Care
Symptom Management

Sriram Yennu, MD, on Cancer-Related Fatigue: Is Open-Labeled Placebo an Effective Treatment?

Sriram Yennu, MD, of The University of Texas MD Anderson Cancer Center, discusses the placebo response in patients with advanced cancer and cancer-related fatigue. His latest findings show that open-labeled placebo was efficacious in reducing cancer-related fatigue and improving quality of life in fatigued patients with advanced cancer at the end of 1 week. The improvement in fatigue was maintained for 4 weeks (Abstract 12006).

Advertisement

Advertisement



Advertisement